医学
间质性肺病
肺功能测试
内科学
队列
自身抗体
硬皮病(真菌)
胃肠病学
结缔组织病
肺纤维化
肺
病理
免疫学
疾病
自身免疫性疾病
抗体
接种
作者
Shuo Liu,Melody P. Chung,Brett Ley,Sarah French,Brett M. Elicker,David Fiorentino,Leland W.K. Chung,Francesco Boin,Paul J. Wolters
出处
期刊:Thorax
[BMJ]
日期:2021-07-16
卷期号:76 (12): 1186-1192
被引量:31
标识
DOI:10.1136/thoraxjnl-2020-215918
摘要
Background Peripheral blood leucocyte telomere length (PBL-TL) is associated with outcomes in patients with idiopathic pulmonary fibrosis. Whether PBL-TL is associated with progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD) is unknown. Methods A retrospective observational cohort study was performed using prospectively collected data from 213 patients with SSc followed at the University of California San Francisco (UCSF) Scleroderma Center. PBL-TL was measured by quantitative PCR of DNA isolated from peripheral blood. Associations between PBL-TL and pulmonary function test trends in patients with SSc-ILD were assessed by longitudinal analysis using Generalised Linear Mixed Models. Findings were validated in a cohort of 61 patients with SSc-ILD enrolled in the Stanford University Scleroderma Center database. Results Patients with UCSF SSc with ILD were found to have shorter PBL-TL compared with those without ILD (6554±671 base pairs (bp) vs 6782±698 bp, p=0.01). Shorter PBL-TL was associated with the presence of ILD (adjusted OR 2.1 per 1000 bp TL decrease, 95% CI [1.25 to 3.70], p=0.006). PBL-TL was shorter in patients with SSc-ILD lacking SSc-specific autoantibodies compared with seropositive subjects (6237±647 bp vs 6651±653 bp, p=0.004). Shorter PBL-TL was associated with increased risk for lung function deterioration with an average of 67 mL greater loss in per year for every 1000 bp decrease in PBL-TL in the combined SSc-ILD cohorts (longitudinal analysis, adjusted model: 95% CI −104 mL to −33 mL, p<0.001). Conclusions These findings suggest that telomere dysfunction may be associated with SSc-ILD progression and that PBL-TL measurement may be useful for stratifying risk for SSc-ILD progression.
科研通智能强力驱动
Strongly Powered by AbleSci AI